“…ING1 downregulation was observed in different tumor types (breast, gastric, esophageal, blood, lung and brain) (Gong et al, 2005), whereas protein mislocalization was described in tumors of different origin (Nouman et al, 2002). ING2 expression was reduced in colorectal, hepatocellular carcinoma, prostate, pancreatic, lung cancer and cutaneous melanoma (Nagashima et al, 2001;Lu et al, 2006;Okano et al, 2006). Allelic loss and reduced expression of ING3 have been also reported (Gunduz et al, 2002;Nagashima et al, 2003).…”